+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infliximab"

From
Crohn's Disease Therapeutics Market - Global Forecast 2025-2030 - Product Thumbnail Image

Crohn's Disease Therapeutics Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Axial Spondyloarthritis Market - Global Forecast 2025-2030 - Product Thumbnail Image

Axial Spondyloarthritis Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
Anti-Rheumatics Market - Global Forecast 2025-2030 - Product Thumbnail Image

Anti-Rheumatics Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 192 Pages
  • Global
From
From
From
From
TNF Inhibitors Market - Global Forecast 2025-2030 - Product Thumbnail Image

TNF Inhibitors Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 190 Pages
  • Global
From
From
Psoriasis Biosimilar Market - Global Forecast 2025-2030 - Product Thumbnail Image

Psoriasis Biosimilar Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 197 Pages
  • Global
From
From
From
Ulcerative Colitis Market - Global Forecast 2025-2030 - Product Thumbnail Image

Ulcerative Colitis Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 191 Pages
  • Global
From
From
From
From
TNF Alpha Inhibitors Market Report 2025 - Product Thumbnail Image

TNF Alpha Inhibitors Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Arthritis Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Loading Indicator

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients. Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms. The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more